These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 31722-0428
Last updated: March 13, 2026
What is NDC 31722-0428?
NDC 31722-0428 refers to an injectable drug marketed under the National Drug Code system. This code corresponds to Liraglutide (Saxenda or Victoza), a glucagon-like peptide-1 (GLP-1) receptor agonist. It is prescribed for obesity management (Saxenda) and type 2 diabetes (Victoza).
Current Market Landscape
Market Segments
Obesity management (Saxenda): FDA approved since 2014.
Diabetes treatment (Victoza): FDA approved since 2010.
Sales and Market Share (2022 Data)
Segment
Market Size (USD)
Growth Rate (2022-2027)
Key Players
Estimated Market Share (2022)
Obesity
3.5 billion
10% annually
Novo Nordisk, Eli Lilly
80% (Novo Nordisk)
Diabetes
4.2 billion
8% annually
Novo Nordisk, Lilly
65% (Novo Nordisk)
Competitive Landscape
Main competitors: Novo Nordisk's Saxenda and Victoza, Eli Lilly's comparable GLP-1 agents.
Pricing trends: Stable over recent years, with slight reductions due to biosimilar entries expected in the medium term.
Market Drivers
Increasing prevalence of obesity and type 2 diabetes globally.
Growing FDA acceptance for obesity indications.
Expanded insurance coverage for GLP-1 therapies.
Procurement Channels and Reimbursement Policies
Reimbursement: Widely covered by Medicare and private insurers for both indications.
Pricing strategies: Negotiations with payers influence net prices.
Price Projections (2023–2028)
Current Pricing
Wholesale acquisition cost (WAC): USD 1,200–1,300 per month.
Typical patient out-of-pocket: USD 50–150, depending on insurance.
Projection Factors
Patent and exclusivity status: Patent protection until at least 2030, limiting biosimilar penetration.
Market penetration: Expected to reach 85-90% in diabetes and 75-85% in obesity segments by 2026.
Pricing adjustments: Slight downward pressure anticipated from biosimilar and generic entries starting 2028, with a 10% reduction over five years.
NDC 31722-0428 (Liraglutide) remains dominant in the GLP-1 segment for obesity and diabetes.
Market is highly concentrated with Novo Nordisk holding approximately 80% of the market share.
Wholesale prices are expected to decline gradually from 2024 onward, driven by biosimilar competition.
Revenue will remain robust through 2028, driven by increasing prevalence and expanding indications.
Pricing strategies will heavily influence profit margins amid patent protections until at least 2030.
FAQs
What factors influence the pricing of NDC 31722-0428?
Patent protection status, market competition, insurance reimbursement policies, and biosimilar entry.
When are biosimilars likely to impact the price?
Entry expected around 2028, with initial biosimilar approvals possibly occurring in 2027.
What is the primary revenue driver for this drug?
Growing prevalence of obesity and type 2 diabetes, along with high market penetration in developed markets.
How does insurance coverage affect retail pricing?
Insurance can significantly lower out-of-pocket costs, stabilizing demand despite wholesale price volatility.
Are there regional differences in price projections?
Yes, prices vary due to regional reimbursement policies, regulatory environments, and negotiated discounts; projections focus on US market.
References
[1] IQVIA. (2022). The Impact of Biosimilars on the US Pharmaceutical Market.
[2] FDA. (2023). Approved Drugs Database.
[3] Evaluate Pharma. (2022). Global Market Forecast for GLP-1 Receptor Agonists.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
